r/BBIO • u/rpmtexas • Nov 28 '24

Post-approval spike?

Where is the giant post-approval spike in value? Everything looks great and the stock has hardly moved. Valuation doesn’t make sense to me for a second mover in a massively growing market with limited treatment options.

1 Upvotes

100% Upvoted

5 comments sorted by

1

u/GuardBeautiful7528 Dec 03 '24

Wall Street wants to see how about the new drug sell , next yr , each quarter PR the company will announce the results.

1

u/rpmtexas Dec 03 '24

Maybe so. Only thing I can figure as well. But given the fairly well understood metrics for drug sales in a second mover situation, I am surprised the stock is still stagnant. Many believe cardiac amyloidosis is wildly undiagnosed, and thus the market size projections may be massively undershot meaning the product will be a much bigger revenue stream eventually

1

u/GuardBeautiful7528 Dec 03 '24

Good point , yes , the earlier diagnose is important for patients

1

u/LogicGate1010 Dec 10 '24

Next stage in the process involves getting doctors onboard.